NQR as a target for new antibiotics.

Area of Science:

• Biochemistry
• Microbiology
• Drug Discovery

Background:

• Antimicrobial resistance (AMR) necessitates novel drug targets.
• The respiratory enzyme Na+/NQR (NQR) is essential for ATP generation in many pathogenic bacteria.
• NQR is absent in humans, making it an attractive, selective drug target.

Purpose of the Study:

• To review the significance of NQR as a drug target.
• To highlight existing and novel NQR inhibitors.
• To emphasize clofazimine as a potential antibiotic candidate.

Main Methods:

• Literature review of NQR function and inhibitors.
• Analysis of existing NQR inhibitor classes (ubiquinone analogs, metal cations).
• Discussion of drug repurposing strategies for NQR inhibition.

Main Results:

• NQR plays a critical role in the pathogenicity of key bacteria like *Vibrio cholerae* and *Pseudomonas aeruginosa*.
• Clofazimine, an FDA-approved drug, demonstrates potent NQR inhibition and antivirulence effects.
• Synthetic analogs of korormicin show reduced cytotoxicity.

Conclusions:

• NQR is a validated and vital target for developing new antibiotics against resistant bacteria.
• Clofazimine represents a promising lead compound for repurposing as an anti-infective agent.
• Targeting NQR offers a viable strategy to combat the growing threat of AMR.